Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AvePoint (AVPT) Research & Development (2020 - 2025)

AvePoint (AVPT) has disclosed Research & Development for 6 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 0.99% to $13.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.6 million through Dec 2025, up 7.98% year-over-year, with the annual reading at $52.6 million for FY2025, 7.98% up from the prior year.
  • Research & Development for Q4 2025 was $13.0 million at AvePoint, down from $13.9 million in the prior quarter.
  • The five-year high for Research & Development was $19.6 million in Q3 2021, with the low at $3.9 million in Q2 2021.
  • Average Research & Development over 5 years is $10.1 million, with a median of $9.3 million recorded in 2023.
  • The sharpest move saw Research & Development soared 554.28% in 2021, then plummeted 53.1% in 2022.
  • Over 5 years, Research & Development stood at $4.5 million in 2021, then skyrocketed by 66.57% to $7.5 million in 2022, then rose by 25.3% to $9.4 million in 2023, then surged by 36.81% to $12.9 million in 2024, then grew by 0.99% to $13.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $13.0 million, $13.9 million, and $13.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.